---
input_text: 'Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N,
  SHH type and poor survival independent of treatment strategies. BACKGROUND: Outcome
  of children with medulloblastoma (MB) and Fanconi Anemia (FA), an inherited DNA
  repair deficiency, has not been described systematically. Treatment is complicated
  by high vulnerability to treatment-associated side effects, yet structured data
  are lacking. This study aims at giving a comprehensive overview about clinical and
  molecular characteristics of pediatric FA MB patients. METHODS: Clinical data including
  detailed information on treatment and toxicities of six previously unreported FA
  MB patients were supplemented with data of 16 published cases. RESULTS: We identified
  22 cases of children with FA and MB with clinical data available. All MBs with subgroup
  reporting were SHH-activated (n=9), confirmed by methylation profiling in five patients.
  FA MB patients exclusively belonged to complementation groups FA-D1 (n=16) or FA-N
  (n=3). Patients were treated with postoperative chemotherapy only (50%) or radiotherapy
  (RT)+-chemotherapy (27%). 23% did not receive adjuvant therapy. Excessive treatment-related
  toxicities were frequent. Severe hematological toxicity occurred in 91% of patients
  treated with alkylating chemotherapy, while non-alkylating agents and RT were less
  toxic. Median overall survival (OS) was 1 year (95%CI 0.3-1.8). 1-year-progression-free-survival
  (PFS) was 26.3+-10.1% and 1-year-OS was 42.1+-11.3%. Adjuvant therapy prolonged
  survival (1y-OS/1y-PFS 0%/0% without adjuvant therapy vs. 53.3+-12.9%/33.3+-12.2%
  with adjuvant therapy, p=0.006/p=0.086). CONCLUSIONS: MB in FA patients is strongly
  associated with SHH activation and FA-D1/FA-N. Despite the dismal prognosis, adjuvant
  therapy may prolong survival. Non-alkylating chemotherapy and RT are feasible in
  selected patients with careful monitoring of toxicities and dose adjustments. Curative
  therapy for FA MB-SHH remains an unmet medical need.'
raw_completion_output: |-
  primary_disease: Medulloblastoma (MB)

  medical_actions: postoperative chemotherapy; radiotherapy; adjuvant therapy; monitoring of toxicities; dose adjustments

  symptoms: excessive treatment-related toxicities; severe hematological toxicity

  chemicals: alkylating chemotherapy; non-alkylating agents

  action_annotation_relationships: postoperative chemotherapy TREATS Medulloblastoma IN children with Fanconi anemia; radiotherapy TREATS Medulloblastoma IN children with Fanconi anemia; adjuvant therapy PREVENTS progression IN Medulloblastoma; monitoring of toxicities PREVENTS excessive treatment-related toxicities IN Medulloblastoma; dose adjustments PREVENTS severe hematological toxicity IN Medulloblastoma; alkylating chemotherapy CAUSES severe hematological toxicity IN Medulloblastoma; non-alkylating agents PREVENT severe hematological toxicity IN Medulloblastoma
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  non-alkylating agents PREVENT severe hematological toxicity IN Medulloblastoma

  ===

extracted_object:
  primary_disease: MONDO:0007959
  medical_actions:
    - postoperative chemotherapy
    - MAXO:0000014
    - adjuvant therapy
    - monitoring of toxicities
    - dose adjustments
  symptoms:
    - excessive treatment-related toxicities
    - severe hematological toxicity
  chemicals:
    - alkylating chemotherapy
    - non-alkylating agents
  action_annotation_relationships:
    - subject: postoperative chemotherapy
      predicate: TREATS
      object: HP:0002885
      qualifier: MONDO:0019391
      object_qualifier: children
      subject_extension: chemotherapy
    - subject: MAXO:0000014
      predicate: TREATS
      object: HP:0002885
      qualifier: MONDO:0019391
      object_qualifier: in children
    - subject: adjuvant therapy
      predicate: PREVENTS
      object: progression
      qualifier: MONDO:0007959
    - subject: monitoring of toxicities
      predicate: PREVENTS
      object: excessive treatment-related toxicities
      qualifier: MONDO:0007959
    - subject: dose adjustments
      predicate: PREVENTS
      object: severe hematological toxicity
      qualifier: MONDO:0007959
      object_qualifier: severe
    - subject: <chemotherapy>
      predicate: <CAUSES>
      object: <severe hematological toxicity>
      qualifier: <Medulloblastoma>
      subject_qualifier: <>
      object_qualifier: <severe>
      subject_extension: <alkylating>
      object_extension: <>
    - predicate: PREVENTS
      object: severe hematological toxicity
      qualifier: MONDO:0007959
      object_qualifier: severe
      subject_extension: non-alkylating agents
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: HP:0000822
    label: hypertension
  - id: MAXO:0001298
    label: therapy
  - id: HP:0040012
    label: Increased chromosomal breakage
  - id: MONDO:0004631
    label: Tongue cancer (TC)
  - id: CHEBI:4735
    label: EDTA
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0025085
    label: Blood in stool
  - id: HP:0000568
    label: Microphthalmia
  - id: HP:0000482
    label: microcornea
  - id: HP:0000508
    label: ptosis
  - id: HP:0011496
    label: limbal neovascularization
  - id: HP:0001097
    label: keratoconjunctivitis sicca
  - id: CHEBI:62932
    label: Mycophenolate
  - id: MONDO:0008903
    label: Lung Cancer
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0032169
    label: severe infections
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: MONDO:0005109
    label: HIV
  - id: HP:0001622
    label: Preterm delivery
  - id: HP:0100601
    label: Eclampsia
  - id: MONDO:0043455
    label: Hereditary hematological malignancy (HHM)
  - id: MONDO:0043797
    label: Spinal Cord Injury (SCI)
  - id: CHEBI:27306
    label: Vitamin B6
  - id: HP:0001915
    label: aplastic anemia
  - id: MONDO:0001056
    label: Gastric cancer
  - id: MAXO:0001193
    label: Esophagogastroduodenoscopy
  - id: CHEBI:31941
    label: Oxaliplatin
  - id: HP:0012126
    label: Gastric cancer
  - id: MONDO:0005575
    label: Colorectal Cancer
  - id: CHEBI:46345
    label: 5-fluorouracil (5-FU)
  - id: CHEBI:15640
    label: Folinic acid
  - id: HP:0008209
    label: Premature ovarian insufficiency (POI)
  - id: HP:0000026
    label: Testicular failure
  - id: CHEBI:81569
    label: Follicle-stimulating hormone (FSH)
  - id: CHEBI:74539
    label: Luteinizing hormone (LH)
  - id: MONDO:0010651
    label: myelodysplastic syndromes (MDS)
  - id: MAXO:0000079
    label: genetic counseling
  - id: MONDO:0018881
    label: myelodysplastic syndromes
  - id: MAXO:0010033
    label: cord blood transplantation
  - id: CHEBI:50443
    label: hematopoietic stem cells (HSC)
  - id: MONDO:0000159
    label: Bone marrow failure syndromes
  - id: HP:0001903
    label: Anemia
  - id: MONDO:0007959
    label: Medulloblastoma (MB)
  - id: HP:0002885
    label: Medulloblastoma
